Here's another good one from Ed Silverman's Pharmalot blog. It is a survey of 211 pharma execs done by Cegedim Dendrite reporting on their goals & challenges. Some of the responses may be surprising to you.
For example, the leading fret of these executives (40%) was whether their strategy for gaining market access was solid or not. This took higher priority in their thinking than other potential weaknesses in their business model (35%) or pipeline holes (24%) and generic competition (16%). That may be a little surprising given how much ink the patent cliff, innovation gap and healthcare reform (biosimilars) has been given recently.
Read the survey to find out more on whom these execs consider to be their primary customers and which forms of social media they use.
Published by Bruce Lehr July 14th 2010.